Clio P. Mavragani
Cited by
Cited by
Sjögren’s syndrome
CP Mavragani, GE Fragoulis, HM Moutsopoulos
The Autoimmune Diseases, 495-510, 2014
The geoepidemiology of Sjögren's syndrome
CP Mavragani, HM Moutsopoulos
Autoimmunity reviews 9 (5), A305-A310, 2010
A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies
M Dastmalchi, C Grundtman, H Alexanderson, CP Mavragani, ...
Annals of the rheumatic diseases 67 (12), 1670-1677, 2008
Augmented interferon‐α pathway activation in patients with Sjögren's syndrome treated with etanercept
CP Mavragani, TB Niewold, NM Moutsopoulos, SR Pillemer, SM Wahl, ...
Arthritis & Rheumatism: Official Journal of the American College of …, 2007
The management of Sjögren's syndrome
CP Mavragani, NM Moutsopoulos, HM Moutsopoulos
Nature clinical practice Rheumatology 2 (5), 252-261, 2006
Activation of the type I interferon pathway in primary Sjogren’s syndrome
CP Mavragani, MK Crow
Journal of autoimmunity 35 (3), 225-231, 2010
Central nervous system involvement in Sjögren’s syndrome
FC Soliotis, CP Mavragani, HM Moutsopoulos
Annals of the Rheumatic Diseases 63 (6), 616-620, 2004
Type I and II interferon signatures in Sjogren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis
A Nezos, F Gravani, A Tassidou, EK Kapsogeorgou, M Voulgarelis, ...
Journal of autoimmunity 63, 47-58, 2015
Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use
S Fragkioudaki, CP Mavragani, HM Moutsopoulos
Medicine 95 (25), 2016
Conventional therapy of Sjogren’s syndrome
CP Mavragani, HM Moutsopoulos
Clinical reviews in allergy & immunology 32 (3), 284-291, 2007
B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome
A Nezos, A Papageorgiou, G Fragoulis, D Ioakeimidis, M Koutsilieris, ...
Journal of autoimmunity 51, 89-98, 2014
Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon‐β/α ratios in rheumatoid arthritis patients: A post hoc …
CP Mavragani, DT La, W Stohl, MK Crow
Arthritis & Rheumatism: Official Journal of the American College of …, 2010
Expression of long interspersed nuclear element 1 retroelements and induction of type I interferon in patients with systemic autoimmune disease
CP Mavragani, I Sagalovskiy, Q Guo, A Nezos, EK Kapsogeorgou, P Lu, ...
Arthritis & rheumatology 68 (11), 2686-2696, 2016
Endocrine alterations in primary Sjogren's syndrome: an overview
CP Mavragani, GE Fragoulis, HM Moutsopoulos
Journal of autoimmunity 39 (4), 354-358, 2012
Sjögren’s syndrome: autoantibodies to cellular antigens
CP Mavragani, AG Tzioufas, HM Moutsopoulos
International archives of allergy and immunology 123 (1), 46-57, 2000
Cardiovascular disease in systemic lupus erythematosus: a comprehensive update
M Giannelou, CP Mavragani
Journal of autoimmunity 82, 1-12, 2017
Predicting the outcome of Sjogren’s syndrome-associated non-Hodgkin’s lymphoma patients
A Papageorgiou, DC Ziogas, CP Mavragani, E Zintzaras, AG Tzioufas, ...
PloS one 10 (2), e0116189, 2015
Antibody response to the human stress protein BiP in rheumatoid arthritis
MD Bodman-Smith, VM Corrigall, E Berglin, HR Cornell, AG Tzioufas, ...
Rheumatology 43 (10), 1283-1287, 2004
Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome
RA Fava, SM Kennedy, SG Wood, AI Bolstad, J Bienkowska, A Papandile, ...
Arthritis research & therapy 13 (6), R182, 2011
Stress, coping strategies and social support in patients with primary Sjögren’s syndrome prior to disease onset: a retrospective case–control study
D Karaiskos, CP Mavragani, S Makaroni, E Zinzaras, M Voulgarelis, ...
Annals of the rheumatic diseases 68 (1), 40-46, 2009
The system can't perform the operation now. Try again later.
Articles 1–20